NFKB1 and colorectal carcinoma: Next, VEGFA, CASP3, MYC, CYP1Y1, and NFKB1 were identified as key targets of the CHs in the treatment of CRC, with their contributions in the PPI network (Figure 4) and prognostic significance in CRC patients (Figure 5).